Dupilumab may be an alternative option in the treatment of acquired reactive perforating collagenosis combined with AD

The management of acquired reactive perforating collagenosis (ARPC) is challenging. Here, we shared two cases of ARPC combined with elderly atopic dermatitis (AD) that did not respond well to conventional treatment but responded well to the monotherapy of dupilumab, which suggests that dupilumab may...

Descripción completa

Detalles Bibliográficos
Autores principales: Ying, Yang, Shuang, Chen, Zhen‐Ying, Zhang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926492/
https://www.ncbi.nlm.nih.gov/pubmed/34953055
http://dx.doi.org/10.1002/iid3.574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926492/
https://www.ncbi.nlm.nih.gov/pubmed/34953055
http://dx.doi.org/10.1002/iid3.574

Ejemplares similares